Clik here to view.
Chugai’s ALK Inhibitor “Alectinib,” New Drug Application Submitted for ALK...
TOKYO Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO:...
View ArticleClik here to view.
Cost-Utility Analysis Projects CARILLON Mitral Contour System as a Cost...
KIRKLAND, Wash. The CARILLON® Mitral Contour System® is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard...
View ArticleClik here to view.
U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New...
View ArticleClik here to view.
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by...
TOKYO & LUGANO, Switzerland Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai...
View ArticleClik here to view.
Acelity Partners with GHD to Expand Access to Advanced Wound Dressing...
SAN ANTONIO Acelity, a global wound care and regenerative medicine company, today announced that it has entered into a strategic commercial partnership with GHD GesundHeits GmbH Deutschland (GHD) to...
View ArticleClik here to view.
武田公司用于复发/难治多发性骨髓瘤患者的 ixazomib列入美国FDA优先评审
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，ixazomib已列入美国食品药品管理局(FDA)的新药申请(NDA)优先评审，ixazomib是首个口服蛋白酶体抑制剂类研究药物，用于治疗复发和/或难治多发性骨髓瘤患者。 武田法规事务副总裁Melody Brown表示：“美国和欧洲的监管部门都认定，ixazomib...
View ArticleClik here to view.
Gencia and Takeda Team to Discover and Develop Novel Class of Mitochondrial...
CHARLOTTESVILLE, Va. & OSAKA, Japan Gencia LLC and Takeda Pharmaceutical Company Limited announced today a partnership to develop a new class of small molecule drugs as potential treatments for...
View ArticleClik here to view.
雅培斥资2.5亿美元收购Jean Boulle集团控股的二尖瓣生产商Tendyne Holdings，印证该集团从采矿到医疗技术都能取得重大发现
卢森堡 Jean Boulle集团(www.jeanboullegroup.com) 下属的医疗技术公司和Tendyne Holdings, Inc. (“Tendyne”)的创始投资者Jean Boulle Medtech Ltd欣然宣布，雅培公司(Abbott Laboratories, NYSE: ABT) 已经完成对Tendyne...
View ArticleClik here to view.
Article 0
ルクセンブルク （ビジネスワイヤ） — Jean Boulleグループ（www.jeanboullegroup.com）の医療技術企業でTendyne Holdings, Inc.（以下「Tendyne」）の設立時投資企業であるJean Boulle Medtech Ltd は、アボット・ラボラトリーズ（NYSE:...
View ArticleClik here to view.
The World Egg Bank Now Offers the Most Advanced Genetic Testing Available in...
PHOENIX The World Egg Bank Inc. has announced the first testing of banked egg donors and recipients to reduce the incidence of having a child with a genetic disease. The World Egg Bank has partnered...
View ArticleClik here to view.
Jubilant DraxImage Signs Term Sheet with Cyclopharm for Exclusive License to...
MONTREAL & SYDNEY Jubilant DraxImage Inc. (“DraxImage”) and Cyclopharm Limited (“CYC”) are pleased to announce the signing of a term sheet, subject to satisfactory due diligence and execution of...
View ArticleClik here to view.
Reduced Cheekbone! Increased Happiness! TL Cheekbone Reduction
SEOUL, South Korea The whole world know Korea’s the best at facial contouring . Facial contouring surgery is attracting a lot people who want to improve the harsh look caused by their edgy facial...
View ArticleClik here to view.
VPS Healthcare第三届国际肿瘤会议吸引900多位代表与会
阿拉伯联合酋长国阿布扎比 (美国商业资讯)–综合性医疗保健提供商VPS Healthcare召开了其第三届国际肿瘤会议，会议主题是“通过早期检测和预防为癌症治疗导航”。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿： http://www.businesswire.com/news/home/20150914005450/zh-CN/ VPS...
View ArticleClik here to view.
米FDA、再発性／難治性多発性骨髄腫患者に対する武田薬品のイキサゾミブに優先審査の指定を与える
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ）– 武田薬品工業株式会社（TSE: 4502）は本日、米食品医薬品局（FDA）がイキサゾミブの新薬承認申請（NDA）に優先審査の指定を与えたと発表しました。イキサゾミブは再発性もしくは難治性または両方の多発性骨髄腫を抱える患者の治療を目的とする初の経口プロテアソーム阻害薬としての治験薬です。...
View ArticleClik here to view.
Technavio Reports the Demand for Contactless Biometrics Will Enhance the...
LONDON Technavio has published a new report on the biometric market in BRIC countries, which is expected to grow at a CAGR of over 23% from 2015-2019. About the Report The latest report by Technavio...
View ArticleClik here to view.
Physio-Control to Acquire HeartSine®
REDMOND, Wash. Physio-Control has reached an agreement with HeartSine Technologies to acquire the Northern Ireland-based automated external defibrillator (AED) manufacturer, the companies announced...
View ArticleClik here to view.
VPSヘルスケアの第3回国際腫瘍学大会に900人以上の代表が出席
アラブ首長国連邦アブダビ （ビジネスワイヤ） — 統合型ヘルスケアプロバイダーのVPSヘルスケアは、「早期発見と早期予防でがん治療のかじ取りをする」というテーマで第3回国際腫瘍学大会を開会しました。 このSmart News Release（スマート・ニュース・リリース）にはマルチメディアのコンテンツが含まれています。リリース全文はこちらから：...
View ArticleClik here to view.
Jubilant DraxImage与 Cyclopharm签署排他性授权条款清单，在美国推广Technegas
蒙特利尔和悉尼 — (美国商业资讯) — Jubilant DraxImage Inc. (“DraxImage”)与Cyclopharm Limited (“CYC”)欣然宣布签署一份条款清单，DraxImage获得在美国推广和分销Technegas 的排他性授权，该清单有待确定性协议得到满意的尽职调查和执行，以及其他必要的审批。DraxImage将协助CYC开展...
View ArticleClik here to view.
Jubilant DraxImage、米国でTechnegasを上市するための独占的ライセンスの条件規定書をCyclopharmと取り交わす
モントリオール & シドニー — （ビジネスワイヤ） — Jubilant DraxImage Inc.（以下「DraxImage」）とCyclopharm...
View ArticleClik here to view.
Yabao Pharmaceuticals and Primary Peptides Announce Exclusive China Partnership
BEIJING & VANCOUVER, British Columbia Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, today announced an exclusive license with...
View Article